tbuckley/cabot-search huggingface dataset:
Abstract 631: Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody
Authors: Giovanni Pacchiana, Cristina Chiriaco, Maria C. Stella, Fiorella Petronzelli, Rita De Santis, Maria Galluzzo, Paolo Carminati, Paolo M. Comoglio, Paolo Michieli, Elisa Vigna
Journal: Cancer Research (2011)

Abstract Met, the high affinity receptor for Hepatocyte Growth Factor (HGF), is one of the most frequently activated tyrosine kinases in human cancer and a validated target for cancer therapy. We previously developed a mouse monoclonal antibody directed against the extracellular portion of Met (DN-30) that induces Met proteolytic cleavage (receptor ‘shedding’) followed by proteasome-mediated receptor degradation, leading to inhibition of HGF/Met-mediated biological activities. However, DN-30 binding to Met also results in partial activation of the Met kinase due to antibody-mediated receptor dimerization. To safely harness the therapeutic potential of DN-30, its shedding activity must be disassociated from its agonistic activity. We have generated a DN-30 Fab fragment that maintains high affinity Met binding, elicits efficient receptor shedding and down-regulation, and does not promote kinase activation. In Met-addicted tumor cell lines, DN-30 Fab displays potent cytostatic and cytotoxic activity in a dose-dependent fashion. DN-30 Fab also inhibits anchorage-independent growth of several tumor cell lines. In mouse tumorigenesis assays using Met-addicted carcinoma cells, intra-tumor administration of DN-30 Fab or systemic delivery of a chemically stabilized form of the same molecule results in reduction of Met phosphorylation and inhibition of tumor growth. These data provide proof-of-concept that monovalency unleashes the full therapeutic potential of the DN-30 antibody and point at DN-30 Fab as a promising tool for Met-targeted therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 631. doi:10.1158/1538-7445.AM2011-631
P07.06 * A CASE OF BING-NEEL SYNDROME PRESENTING AS EPIDURAL METASTASIS
Authors: A. Rigamonti, P. Melzi, D. Vismara, G. Rossi, A. Tetto, A. Salmaggi
Journal: Neuro-Oncology (2014)

In 2005, a 63 year-old man with prior hypertension, started to complain persistent asthenia and weight loss. Blood tests revealed anemia and hypergammaglobulinemia. Immunoelectrophoresis confirmed the presence of monoclonal immunoglobulin M (IgM) with kappa light chain (34 g/L) in the serum. Multiple retroperitoneal lymphoadenopathies were detected. Bone marrow examination disclosed lymphoplasmocytic proliferation with small lymphocytes and plasmacytoid lymphocytes. The patient received 6 cycles of fludarabine, cyclophosphamide and rituximab from November 2005 to July 2006 with partial remission. Maintenance therapy with monthly administration of rituximab was then performed from October 2006 to January 2007. In July 2011 a relapse occured and chemotheraphy with 2-CdA cladribine and rituximab was introduced with complete response. In January 2014 the patient came to our attention complaining a 2 month hystory of difficulties in walking, stifness in the legs, hand clumsiness and episodic urinary urgency. Neurological examination showed mild paraparesis, reduced proprioception in the legs without sensory levels, diffuse hyper-reflexia, bilateral Babinski sign and increased tone in the legs. Serum protein electrophoresis and immunofixation confirmed a gamma band and monoclonal Ig M kappa light chains. Cerebrospinal fluid (CSF) examination revealed 96 cells/mm3 with 90% of lymphocytes, low glucose concentration (31 mg/dL) and increased protein level (1288 mg/dl). CSF cytology and flow cytometry proved negative for malignancy, there was T cell CD5+ predominance in the cells seen. Magnetic resonance imaging (MRI) of the brain showed leptomeningeal enhancement along the brainstem. MRI of the spinal cord showed an enhancing epidural mass spanning levels C2-C4 causing spinal cord compression and associated with mild hyperintensity in the cervical cord on T2-weighted sequences at this level, moreover leptomeningeal enahncement along inferior cervical and upper dorsal spinal cord was present. The patient underwent a decompressive laminectomy at C2-C4. Postoperative course was regular, without complications. Pathological analysis of tissue fragments from the epidural lesion revealed an atypical, diffuse lymphoid infiltrate. Immunohistochemical staining of these cells was positive for CD20, CD79 and partially for CD38, negative for CD10, CD5, CD3, CD23, ciclin D1. Staining for immunoglobulin light chains revealed kappa light chain. These results support the diagnosis of epidural localization of WM. Even if epidural infiltration can occur in lymphoid neoplasms such as Hodgkin's and non Hodgkin's lymphoma, plasmocytoma and multiple myeloma, this has been exceptionally reported in WM (Al-Halabi H, Roberge D American Journal of Hematology 2006, 81: 955-958). In our case pathological analysis of a biopsy specimen confirmed an epidural localization of WM.
THE RELEVANCE TO CLINICAL OUTCOMES AND RISK FACTORS OF PERI-CONTRAST STAINING (PSS) AFTER SECOND GENERATION DES DEPLOYMENT
Authors: Takahiro Tokuda, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Ito, Hiroshi Ishimori, Keisuke Hirano, Masatsugu Nakano, Masahiro Yamawaki, Motoharu Araki, Norihiro Kobayashi, Hideyuki Takimura, Yasunari Sakamoto, Masakazu Tsutsumi, Hiroya Takafuji, Takuro Takama
Journal: Journal of the American College of Cardiology (2015)
AB0812-PC Clinical and epidemiological characteristics of women with breast cancer and aromatase inhibitors treatment who presented hip fracture between 2008-2010
Authors: M. Pacin-Cebral, L. López-Silva, J. Miguel-Carrera, S. Varela-Ferreiro, C. Garcia-Porrua
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The main source of estrogen is produced in peripheral tissues in post-menopausal women. Due to this, lowering estrogen production at peripheral tissues with aromatase inhibitors might be an additional risk factor for osteoporosis and hip fracture. <h3>Objectives</h3> Our aim was to analyzethe clinical and epidemiological characteristics of women who had a hip fracture and had been diagnosed as having breast cancer and treated with IA <h3>Methods</h3> We conducted a retrospective study of the case records of all adults women diagnosed with hip fracture and IA treatment for breast cancer from January 2008 through December 2010. The Hospital Universitario Lucus Augusti is the only referral center for our population. Statistical analyses were performed using SPSS. <h3>Results</h3> Thirteen women who had suffered breast cancer and IA treatment presented hip fracture during the period 2008-2010. From all hip fractures found, 7 were trochanteric, 3 subtrochanteric and 3 had occurred in femoral neck. The median age at the time of fracture was 83 years. All fractures require hospitalization and surgery. The median age at the time of breast cancer diagnosis was 72 years. All patients were treated with third-generation IA and none had been previously diagnosed as having osteoporosis. Five patients (38.4%) received anti-osteoporotic treatment after hip fracture. <h3>Conclusions</h3> Hip fractures occur in those patients with breast cancer and treatment with IA when they have diagnosed in an elderly age (median age 72). In these patients, a better physician awareness looking for risk factor for osteoporosis, especially in elderly people could decrease the number of hip fractures. Treatment after hip fracture should be required. <h3>References</h3> –Salgado BA, Zivian MT. Aromatase inhibitors: side effects reported by 622 women. Breast Cancer Research and Treatment, 2006; 100: abstract 3131 –Miguel-Carrera J, Varela-Prado ME, Bravo-Perez M, Garcia-Porrua C. Características epidemiológicas de los pacientes en tratamiento antiosteoporotico del Centro de Salud de Sarria (Lugo). Cadernos de Atencion Primaria 2011; 18:85-9 –Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. European Guidance for Diagnosis and Management of Osteoporosis in Postmenopausal women. Osteoporosis Int. 2008; 19:399-428 –Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, Mc Closkey EV, Reid DM, Selby P, Wilkins M; National Osteoporosis Guideline Group. Guidelines for diagnosis and management of osteoporosis in postmenopausal women and men from the 50 years in the UK. Maturitas 2009; 62:105-8 <h3>Disclosure of Interest</h3> None Declared
PTU-049 Endoscopic Resection and Stepwise Endoscopic Ablation for early Neoplasia in Barrett’S Oesophagus: outcome in a Large Oesophagus Cancer Centre
Authors: N Fernandopulle, G Horgan, A Bailey, R Marshall, B Sgromo, N Maynard, B Braden
Journal: Gut (2013)

<h3>Introduction</h3> Endoscopic mucosal resection (EMR) followed by radiofrequency ablation (RFA) is now considered standard for treatment of high grade dysplasia (HGD) and intramucosal cancer in Barrett’s oesophagus (BE). Complete ablation of the Barrett’s epithelium is recommended to reduce the risk of metachronous neoplasia. However, RFA is an expensive treatment modality, often requiring repeat procedures and endoscopic surveillance thereafter and may not be necessary in all patients. <h3>Methods</h3> We analysed our database of oesophageal EMR procedures performed for HGD or early cancer from 2008 to 2012. Patients’ demographics, Barrett’s length, histology, number of procedures, remission and complication were assessed. All patients referred for endoscopic treatment of early Barrett’s neoplasia were investigated using EUS to exclude obvious infiltration of deeper structures. EMR was performed using band ligation mucosectomy. Patients were followed up 3 monthly with endoscopy and EMR repeated as required. If no dysplasia was found after a year, follow up interval was increased to 6 months. <h3>Results</h3> 64 patients underwent EMR for HGD (20) or early oesophageal cancer (44) in BE. 149 EMR’s were performed. 48 patients were male (75%), mean age was 70.6years (range 30–87years). 20 patients (31%) with either submucosal or deeper infiltration or poor differentiation in the EMR specimen underwent surgery/chemotherapy or were conservatively managed depending on patient’s fitness, comorbidities and choice. Mean follow-up of the remaining 44 patients undergoing endoscopic therapy was 22.7 month (range 1–55 months). Remission of dysplasia/neoplasia was achieved in 97.9%. Stepwise EMR during follow up resulted in complete ablation of BE in 18 patients (40%) in a mean of 4 sessions. All patients with complete endoscopic Barrett’s ablation had an initial maximal Barrett lengths &lt; 3 cm. 7 patients with long Barrett’s ( &gt; 5cm) received RFA and 7 others are awaiting the procedure. The overall complication rate was low (6.7%) including a stricture after RFA (0.7%), 8 procedural (5.3%, none Hb relevant) and a delayed bleeding (0.7%) but no perforations. All complications were managed endoscopically. <h3>Conclusion</h3> Oesophageal EMR is a safe procedure which can achieve remission of neoplasia. In short segment Barrett’s oesophagus it can also result in complete ablation of BE. Stepwise endoscopic resection for ablation has a low complication rate when performed in 3 monthly follow-up intervals. <h3>Disclosure of Interest</h3> None Declared
Abstract P4-09-14: Invasive Lobular Carcinoma Is a Prototype of Luminal A Breast Cancer Subtype and Rare in Korea
Authors: S-Y Jung, Y Kwon, E-A Kim, KL Ko, KH Shin, KS Lee, IH Park, S Lee, SW Kim, H-S Kang, J. Ro
Journal: Cancer Research (2010)

Abstract Purpose Invasive lobular carcinoma (ILC) is known to be the second most frequent histologic subtype, occupying 10% of invasive breast cancer in the Western countries. The present study was designed to assess the clinical characteristics and outcomes of ILC compared to general invasive ductal carcinoma (IDC) and the luminal A subtype (LA-IDC). Methods The study population included d 2916 patients with invasive breast cancer consecutively diagnosed at the National Cancer Center, Korea between 2001 and 2008. The clinicopathological characteristics and clinical outcomes were retrospectively reviewed. Results There were 83 pts (2.8%) diagnosed with ILC and 1,088 pts (37.3%) with LA-IDC. Mean age was 48.2 years of all patients, 48.3 years of ILC group and 47.9 years of LA-IDC group. The ILC patients presented with a larger tumor size (≥T2, 59.8% vs. 38.8%, P=0.001), lower histologic grade (HG 1 or 2, 90.4% vs 64.4%, P&amp;lt;0.001), more often estrogen receptor (ER) and progesterone receptor (PgR) positivity (ER+, 90.4% vs. 64.4%, P&amp;lt;0.001; PgR+, 71.1% vs. 50.1%, P&amp;lt;0.001), HER2 negativity (97.5% vs. 74.9%, P&amp;lt;0.001), lower Ki-67 expression (10.3% ± 10.6% vs. 20.6% ± 19.8%, P&amp;lt;0.001), and luminal A subtypes (91.4% vs. 51.2%, P&amp;lt;0.001) compared to the IDC group. Six (7.2%) ILC patients and 359 (12.7%) IDC patients developed disease recurrence with a median follow-up of 56.4 months (range 4.9-136.6 months). Although ILC showed similar prognosis to IDC in general (5-year DFS rate, 91.7% in ILC vs. 87.4% in IDC, P=0.31; 5-year OS rate, 93.6% in ILC vs. 92.5% in IDC, P=0.38), its outcome was closer to LA-IDC, and better than non LA-IDC (LA-IDC (ref); ILC, HR 0.77 in recurrence, 95% CI 0.31-1.90, P=0.57; HR 0.75 in death, 95% CI 0.18-3.09, P=0.70; non LA-IDC, HR 1.69 in recurrence, 95% CI 1.23-2.33, P=0.001; HR 1.50 in death, 95% CI 0.97-2.33, P=0.07) in univariate and multivariate analysis. Conclusions ILC is a very rare histologic subtype of breast cancer in Korea compared to the Western countries and has distinctive clinicopathological characteristics similar to those of LA-IDC. Acknowledgement: supported by NCC grant #0910320 Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-09-14.
Toxigenic Corynebacterium ulcerans in a fatal human case and her feline contacts, France, March 2014
Authors: S Vandentorren, N Guiso, E Badell, P Boisrenoult, M Micaelo, G Troché, P Lecouls, M J Moquet, O Patey, E Belchior
Journal: Eurosurveillance (2014)

In March 2014, a person in their eighties who was diagnosed with extensive cellulitis due to toxigenic Corynebacterium ulcerans died from multiple organ failure. Environmental investigation also isolated C. ulcerans in biological samples from two stray cats in contact with the case. This finding provides further evidence that pets can carry toxigenic C. ulcerans and may be a source of the infection in humans.
Implications of the CMS Final Meaningful Use Information Technology Rule
Authors: Tamar Thompson, Jay A Harolds
Journal: Clinical Nuclear Medicine (2010)

The importance of Health Information Technology and the Electronic Medical Record were discussed in the October issue of Clinical Nuclear Medicine (Henkin and Harolds, Clin Nucl Med. 2010;35). Since that article was written the Final Rule has been issued on what constitutes the meaningful use of certain information technology, such that it would qualify for an incentive payment. Since billions of dollars will be used for such payments, the issuance of the Final Rule has been eagerly anticipated.
Abstract P6-06-01: Relationship between Vitamin D Deficiency and Breast Cancer Histology: A Retrospective Database Review
Authors: C Weinstock, Y Zhu, T Bao, RR Buras, NN Hanna, K Tkaczuk, S. Chumsri
Journal: Cancer Research (2010)

Abstract Background: Vitamin D deficiency has recently been shown to be correlated with high rates of developing breast cancer (Chen P et al, Breast Cancer Res Treat; Oct 2009). However, the association between the degree of vitamin D deficiency and specific histological subtypes of breast cancer remains unclear. Preclinical data has suggested that vitamin D plays an essential role in the terminal differentiation of breast cancer cells, and thus vitamin D deficiency would be associated with the pathogenesis of estrogen receptor negative tumors (Welsh J et al, Journal of Steroid Biochem Mol Biol; Feb 2003), in particular triple-negative tumors, which are associated with a particularly aggressive clinical course. Methods: Beginning in July 2008, the majority of newly diagnosed breast cancer patients at University of Maryland Greenebaum Cancer Center had Vitamin D 25-OH levels testedon initial presentation to the clinic. We conducted a retrospective chart review to obtain information about tumor histology and vitamin D levels in these patients. Results: We include data on 71 patients who presented with newly-diagnosed breast carcinoma or DCIS between June 2008 and December 2009. Average age at diagnosis was 57 (range 36-87), and 58% of patients were African American. Stage distribution of the cohort included; DCIS-3%, stage I-15%, stage II-41%, stage III-28%, and stage IV-10%. Overall, 80% of the patients were vitamin D deficient at diagnosis, with vitamin D levels under 30 ng/ml, and 57% had levels under 20 ng/ml. Patients with triple-negative tumors were the most likely to be vitamin D deficient at diagnosis (90%) compared to hormone receptor-positive patients (75%), and they had the lowest mean and median vitamin D levels compared to all other patients. Percentage of patients with Vitamin D deficiency Vitamin D level by histological subtype Hormone receptor-positive patients were significantly more likely to have normal vitamin D levels at diagnosis and significantly less likely to have severe deficiency (level &amp;lt;10 ng/ml) than those with hormone receptor-negative tumors (p=0.037). African-American women in this cohort were also more likely to be severely vitamin D deficient, with levels &amp;lt;10 ng/ml, than were Caucasian women (34% vs. 7%, p=0.048). Conclusion: Vitamin D deficiency is common among patients with newly-diagnosed breast cancer. Patients with triple-negative tumors may have a higher likelihood of being vitamin D deficient than patients with other histological subtypes. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-06-01.
Aseptic Necrosis
Authors: CHRISTOPHE VAN DE WIELE, RUDÍ ANDRÉ DIERCKX, L. NOENS, M. SIMONS
Journal: Clinical Nuclear Medicine (1997)

Based on the data by Armas et al, avascular necrosis, a not uncommon treatment-associated complication in patients with lymphoma, it should be easily distinguishable from osseous lymphomatous involvement in patients with Ga-67 avid lymphoma. In avascular necrosis, Ga-67 uptake will be either absent, decreased, or normal, whereas in lymphoma Ga-67 uptake will be increased. The authors present a patient with Hodgkin's disease who had new foci of simultaneously increased Ga-67 and Tc-99m MDP uptake because of avascular necrosis as proven by biopsy and long-term follow-up. The authors hypothesize that a possible explanation for the discrepancy between this patient report and the series by Armas et al may be that increased Ga-67 is a delayed phenomenon related to healing.
Clinical Utility of Lymphocyte Surface Markers Combined with the Lukes-Collins Histologic Classification in Adult Lymphoma
Authors: Clara D. Bloomfield, Kazimiera J. Gajl-Peczalska, Glauco Frizzera, John H. Kersey, Anne I. Goldman
Journal: New England Journal of Medicine (1979)

To determine whether analysis of lymphocyte surface markers adds clinically useful information to the Lukes-Collins classification of lymphomas, tumors from 107 adults were histologically classified and studied for surface markers. Ninety-six cases were histologically classified as Lukes-Collins B-cell lymphomas; 87 showed B and one showed T surface markers, whereas eight had neither marker. Eleven lymphomas were histologically T-cell tumors; four of the 11 showed T surface markers, and seven had neither marker. Both the Lukes-Collins classification and surface markers identified patient groups with different clinical characteristics, chemotherapeutic responsiveness and survival. However, by combining surface markers and histologic features, additional important therapeutic and prognostic information was obtained. In each histologic class, patients whose lymphomas failed to express immunologically the histologically predicted marker had fewer responses to chemotherapy and shorter survivals than patients whose lymphomas expressed the predicted marker. Our data suggest that the analysis of surface markers in combination with the Lukes-Collins classification identifies many patients who respond poorly to current therapy and who thus require new therapeutic approaches. (N Engl J Med 301:512–518, 1979)
Abstract 5350: Distinction of childhood soft tissue sarcomas with high metastatic potential by miRNAs
Authors: Delia Herrmann, Sorin Armeanu-Ebinger, Steven W. Warmann, Michael Bonin, Ivo Leuschner, Björn Brücher, Jörg Fuchs, Guido Seitz
Journal: Cancer Research (2011)

Abstract Background: Advanced stage alveolar (RMA) and embryonal rhabdomyosarcoma (RME) as well as malignant rhabdoid tumor (MRT) have a poor prognosis. Novel treatment approaches based on an improved understanding of metastatic invasion are required. Aberrant microRNA (miRNA) expression is found in cancer progression and metastatic invasion and may help to identify novel targets. The aim of this study was to identify specific miRNA expression patterns in pediatric soft tissue sarcomas. Methods: We analyzed the expression of 743 miRNAs in 5 RMA, RME, and MRT formalin fixed tissue samples and in the rhabdomyosarcoma (RMS) cell lines Rh30 and RD using an Illumina BeadArray. Differentially expressed miRNAs between RMS and MRT specimens were identified on the basis of the cubic spline algorithm using BeadStudio Software. Selected target miRNAs were transfected with mimic or inhibitor oligonucleotides. Functional analysis was monitored by western blotting, flow cytometry, and migration assays. Results: Principal component analysis as well as Spearman's rank correlation on the set of differentially expressed miRNAs showed tissue-specific clustering. A review of the literature revealed 23 miRNAs promoting and 46 miRNAs suppressing metastatic invasion. Eight miRNAs regulating migration in both directions were also described. In our study, metastatic invasion associated miRNAs miR-9* and miR-221 were overexpressed in RMS tissue samples compared to MRT. miR-200c, which inhibits metastatic invasion, was lower expressed in RMS than in MRT. Transient transfection of RMS cells with a miR-200c mimic resulted neither in a reduction of the direct target ZEB1 nor in an increase of the ZEB1-repressed ectopic E-cadherin expression. Migration of RMS cells after induction of miR-200c was not decreased. Furthermore, inhibition of miR-9* and miR-221 in RMS cell lines did not influence migration characteristics. Conclusions: Pediatric RMS and MRT can be distinguished by their specific miRNA expression pattern. These might also help for an optimized risk stratification of these tumors. A modulation of the metastatic invasion was not possible by the investigated miRNAs. Therefore, regulation of migration seems to be controlled by multiple miRNAs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5350. doi:10.1158/1538-7445.AM2011-5350
TCT-357 Prevalence and Management of Coronary Chronic Total Occlusions in a Tertiary Veterans Affairs Hospital
Authors: Omar M. Jeroudi, Mohammed E. Alomar, Tesfaldet T. Michael, Abdallah El Sabbagh, Vishal G. Patel, Owen Mogabgab, Eric Fuh, Daniel Sherbet, Nathan Lo, Michele Roesle, Bavana Rangan, Shuaib Abdullah, Jeffrey L. Hastings, Jerrold Grodin, Subhash Banerjee, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2013)